Preventive cardiologyEffect of Statin Therapy on Mortality in Patients With Peripheral Arterial Disease and Comparison of Those With Versus Without Associated Chronic Obstructive Pulmonary Disease
Section snippets
Methods
From 1990 to 2006, a total of 3,371 consecutive patients underwent elective vascular surgery at the Erasmus Medical Center, Rotterdam, The Netherlands. Surgical procedures included abdominal aortic surgery (AAA), carotid endarterectomy (CAE), or lower-limb arterial reconstruction (LLR). Patients with AAA surgery underwent infrarenal AAA repair (aortic-to-aortic or aortic-bifurcation prostheses procedures, removal of infected prostheses, and other operations of the abdominal aorta). CEA surgery
Results
Baseline characteristics according to the presence of COPD and statin use were listed in Table 1. Mean age of the 3,371 patients was 66 ± 13 years, and 73% were men. Overall, 24% (n = 810) were statin users. Of the total patients with COPD, 25% used statins, and of patients without COPD, 23%. Statins were more frequently prescribed to patients who underwent CEA and less frequently in patients who underwent LLR (both p <0.001) in patients with and without COPD. Patients who received statins more
Discussion
Results of the present study confirmed the known beneficial effect of statins on short- and long-term mortality in patients with PAD and showed that this effect extended to patients with COPD. We found that intensive therapy was superior to low-dose therapy in reducing short- and long-term mortality in patients with COPD.
Consistent with our findings, several studies have shown that statin therapy reduced the mortality in patients with PAD undergoing vascular surgery.4, 5, 6, 7 We extended these
References (15)
- et al.
The effect of intensified lipid-lowering therapy on long-term prognosis in patients with peripheral arterial disease
J Vasc Surg
(2007) - et al.
Reduction of morbidity and mortality by statins, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers in patients with chronic obstructive pulmonary disease
J Am Coll Cardiol
(2006) - et al.
Influenza and COPD mortality protection as pleiotropic, dose-dependent effects of statins
Chest
(2007) - et al.
Early and late benefits of high-dose atorvastatin in patients with acute coronary syndromes: results from the PROVE IT-TIMI 22 trial
J Am Coll Cardiol
(2005) - et al.
Global strategy for the diagnosis, management, and prevention of COPD—2006 update
Am J Respir Crit Care Med
(2007) - et al.
Lung volumes and forced ventilatory flowsReport Working Party Standardization of Lung Function Tests, European Community for Steel and Coal. Official statement of the European Respiratory Society
Eur Respir J Suppl
(1993) - et al.
Comparison of spirometric reference values
Pediatr Pulmonol
(2004)
Cited by (75)
Effects of Statin Therapy and Dose on Cardiovascular and Limb Outcomes in Peripheral Arterial Disease: A Systematic Review and Meta-analysis
2021, European Journal of Vascular and Endovascular SurgeryRepurposing of statins via inhalation to treat lung inflammatory conditions
2018, Advanced Drug Delivery ReviewsLipid profile and statin use: The paradox of survival after acute exacerbation of chronic obstructive pulmonary disease
2015, American Journal of the Medical SciencesCitation Excerpt :Statins reduce cholesterol levels by inhibiting 3-hydroxy- 3-methylglutaryl coenzyme A (HMG-CoA) reductase and have an established role in the treatment of atherosclerotic disease.14,15 The therapeutic effect of statins on cardiovascular and autoimmune disease seems to be broadly anti-inflammatory, which is also likely to apply to lung diseases in which there is an inflammatory component.11–13 Soyseth et al13 demonstrated over a median follow-up of 1.9 years in 854 consecutive patients with a diagnosis of AECOPD that the HR for mortality in statin users was 0.57 (95% confidence interval, 0.38–0.87).
Statins do not improve lung function decline in COPD?
2014, European Journal of Internal MedicineNew drug therapies for COPD
2014, Clinics in Chest Medicine
Yyette R.B.M. van Gestel and Sanne E. Hoeks were supported by an unrestricted research grant from Lijf & Leven Foundation, Rotterdam, The Netherlands. Dr. Schouten was supported by an unrestricted research grant from The Netherlands Organization of Heart Research and Development (ZonMW), The Hague, The Netherlands.